Finance

Beta
Lists
B1AX34:BVMF
Baxter International Inc Bdr
R$47.45
0.00%
(0.00) 1D
Jun 1, 10:15:48 AM GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for B1AX34...
Mkt. cap
9.59B
Avg. vol.
43.00
Volume
0.00
52-wk high
R$86.19
52-wk low
R$40.96
Shares outstanding
516.47M
No. of employees
38K
Mkt. cap
9.59B
Avg. vol.
43.00
Volume
0.00
52-wk high
R$86.19
52-wk low
R$40.96
Shares outstanding
516.47M
No. of employees
38K
News stories
From sources across the web
Profile
Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois. The company primarily focuses on products to treat chronic and acute medical conditions. The company had 2023 global net sales of $14.8 billion, across three business: "Medical Product and Therapies", "Healthcare Systems and Technologies" and Pharmaceuticals. Baxter's Medical Product and Therapies business comprise two divisions: the first named "Advanced Surgery" that produce technologies to enhance surgeons' technique, increase efficiencies and improve outcomes. The second named "Infusion Therapies and Technologies" produces intravenous products and other products used in the delivery of fluids and drugs to patients. Baxter's Healthcare System and Technologies business has four divisions "Front Line Care", "Digital Platform and Innovations", "Care and Connectivity Solutions" and "Global Services". Baxter's Pharmaceuticals business produce inhalational anaesthetics and other differentiated hospital pharmaceuticals in areas of pain, critical care, anti-infection and oncology. Wikipedia
About Baxter International Inc Bdr
CEOAndrew Hider
Employees37.5K
Founded1931
HeadquartersDeerfield, Illinois, United States
SectorMedical device
Websitebaxter.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
2.81B
2.84B
2.97B
2.70B
Cost of goods sold
1.67B
1.81B
2.01B
1.80B
Cost of revenue
1.67B
1.81B
2.01B
1.80B
Research and development expenses
134.00M
115.00M
116.00M
124.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
628.00M
669.00M
675.00M
658.00M
Operating expense
710.00M
734.00M
741.00M
735.00M
Total operating expenses
2.38B
2.55B
2.76B
2.54B
Operating income
434.00M
287.00M
219.00M
163.00M
Other non operating income
-1.00M
2.00M
3.00M
-1.00M
EBT including unusual items
133.00M
121.00M
-756.00M
-6.00M
EBT excluding unusual items
363.00M
228.00M
161.00M
93.00M
Income tax expense
11.00M
172.00M
279.00M
11.00M
Effective tax rate
8.27%
142.15%
-36.90%
-183.33%
Other operating expenses
-52.00M
-50.00M
-50.00M
-47.00M
Net income
91.00M
-46.00M
-1.13B
-15.00M
Net profit margin
3.24%
-1.62%
-37.93%
-0.56%
Earnings per share
0.59
0.69
0.44
0.36
Interest and investment income
14.00M
10.00M
11.00M
12.00M
Interest expense
-72.00M
-68.00M
-69.00M
-78.00M
Net interest expenses
-58.00M
-58.00M
-58.00M
-66.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
691.00M
524.00M
459.00M
400.00M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer